Literature DB >> 1283606

Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia.

A Kumar1, M B Hay, G A Maier, J W Dyke.   

Abstract

The post-antibiotic effects (PAE) of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin were studied for ten strains of Pseudomonas cepacia isolated from patients with cystic fibrosis. Antibiotic concentrations used for exposure were either the MIC of each agent for the sensitive isolates or the recommended sensitivity breakpoint concentrations for the resistant isolates. After 2 h of exposure, cultures were rapidly diluted 1000-fold to eliminate the antibiotic. Out of the ten isolates, there were eight sensitive to ceftazidime, six to ciprofloxacin, six to imipenem, nine to piperacillin and five to tobramycin. All antibiotics tested demonstrated PAE for some isolates of P. cepacia, however, each antibiotic failed to produce a PAE for at least one isolate. The mean PAE was 1.35 h for ceftazidime, 2.38 h for ciprofloxacin, 2.39 h for imipenem, 2.16 h for piperacillin and 1.77 h for tobramycin. Imipenem demonstrated PAE of > or = 0.5 h for all sensitive isolates tested; ceftazidime, piperacillin, ciprofloxacin and tobramycin demonstrated PAE of > or = 0.5 h for 6/8, 8/9, 5/6 and 2/5 sensitive isolates, respectively. These data indicate that several antibiotics have significant (> or = 0.5 h) PAE for isolates of P. cepacia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283606     DOI: 10.1093/jac/30.5.597

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment.

Authors:  A L Walsh; M D Smith; V Wuthiekanun; N J White
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

2.  Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients.

Authors:  J Riethmueller; M Ballmann; T W Schroeter; P Franke; R von Butler; A Claass; S Junge; G Doering; M Stern
Journal:  Infection       Date:  2009-09-05       Impact factor: 3.553

Review 3.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

4.  Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent.

Authors:  Y Niwano; T Tabuchi; K Kanai; H Hamaguchi; K Uchida; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.